Blood test could steer cancer treatment to right drug
NCT ID NCT06314997
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether a blood test that looks for genetic changes in circulating tumor cells can help doctors choose the right targeted therapy for colorectal cancer. 150 participants will either get treatment guided by the blood test or standard care. The goal is to see if the blood test approach improves response rates at 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- panitumumab (EGFR inhibitor)
- What this could lead to
- If successful, this approach could help doctors choose more effective treatments for colorectal cancer by using a simple blood test.
- What could go wrong
- This is a phase II trial with only 150 participants, so results are preliminary. The blood test may not reliably predict which treatment works best.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Natalia Malara
RECRUITINGGermaneto, Italy, 88100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?